Full Transcript: Medpace Hldgs Q2 2026 Earnings Call
On Thursday, Medpace Hldgs (NASDAQ: MEDP ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary Medpace Hldgs reported Q2 2026 revenue of $707.3 million, a 17.2% year-over-year increase, with a six-month revenue of $1.41 billion, up 21.7%. Net income for Q2 was $121.4 million, a 34.5% increase from the previous year, driven by a lower tax rate and higher interest income. The company updated its 2026 guidance, expecting total revenue between $2.805 billion and $2.885 billion, with an EBITDA range of $618 million to $642 million. Net new business awards increased by 28.2% year-over-year to $795.7 million...
On Thursday, Medpace Hldgs (NASDAQ: MEDP ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation.
The full earnings call is available at Summary Medpace Hldgs reported Q2 2026 revenue of $707.3 million, a 17.2% year-over-year increase, with a six-month revenue of $1.41 billion, up 21.7%. Net income for Q2 was $121.4 million, a 34.5% increase from the previous year, driven by a lower tax rate and higher interest income. The company updated its 2026 guidance, expecting total revenue between $2.805 billion and $2.885 billion, with an EBITDA range of $618 million to $642 million. Net new business awards increased by 28.2% year-over-year to $795.7 million, with a book-to-bill ratio of 1.13, indicating strong demand.
Cancellations decreased significantly, benefiting net bookings, while oncology bookings saw a substantial increase, surpassing metabolic programs. Management highlighted an improved business environment with strong RFPs and a constructive outlook for 2027, despite uncertainties in cancellation trends. The company's headcount growth is expected to continue, with significant expansion in the US and Asia Pacific regions, including India for cost efficiency. Full Transcript OPERATOR Good day, ladies and gentlemen, and welcome to the Medpace Hldgs second quarter 2026 earnings conference call.
At this time, all participants are in a listen-only mode. After the speakers' remarks, there will be a question-and-answer session. If you'd like to ask a question, please press star 11 on your phone. If your question has been answered and you'd like to remove yourself from the queue, simply press star 11 again.
As a reminder, this call is being recorded. I would now like to introduce your host for today's conference call, David Rue, Medpace Hldgs' Director of Investor Relations. You may begin. David Rue, Director of Investor Relations Good morning and thank you for joining Medpace Hldgs' second quarter 2026 earnings conference call.
Also on the call today is our CEO August Trundle and our CFO Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve inherent assumptions with known and unknown risks and uncertainties as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed in our Form 10-K and other filings with the SEC.
Please note that we assume no obligation to update forward-looking statements even if estimates change accordingly. You should not rely on any of today's forward-looking statements as representing our views as of any date after today. During this call we will also be referring to certain non-GAAP financial measures. These non-GAAP measures are not superior to or a replacement for the comparable GAAP measures, but we believe these measures help investors gain a more complete understanding of results.
A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available in the earnings press release and earnings call presentation slides provided in connection with today's call. The slides are available in the Investor Relations section of our website at investor.medpace.com. With that, I would now like to turn the call over to August Trundle. August Trundle, CEO Good day, everyone.
The business environment was strong in Q2 2026. Cancellations were well behaved and supported a record quarter for net bookings. RFPs were up sequentially and year over year, generating high quality opportunities. Initial award notifications remained solid although they declined sequentially from a very strong Q1.
Overall, the environment remains constructive into July and we are making good progress in positioning the business for 2027. Kevin will now review our financial results from Q2. Kevin M. Brady, Chief Financial Officer Thank you and good morning to everyone listening in.
Revenue was $707.3 million in the second quarter of 2026. This represented a year-over-year increase of 17.2%. Revenue for the six months ended June 30, 2026 was 1.41 billion and increased 21.7%. EBITDA of 153.4 million increased 17.6% compared to 130.5 million in the second quarter of 2025.
Year to date, EBITDA was $302.8 million and increased 21.5% from the comparable prior year period. EBITDA margin for the second quarter was 21.7% compared to 21.6% in the prior year period. Year to date, EBITDA margin of 21.4% was flat compared to the prior year period as the impact of higher reimbursable costs was offset primarily by lower employee-related costs. In the second quarter of 2026, net income of $121.4 million increased 34.5% compared to net income of $90.3 million in the second quarter of 2025.
Net income growth above EBITDA growth was primarily driven by a lower effective tax rate and higher interest income compared to the prior year period. Year to date, net income was 245.2 million compared to 204.9 million in the comparable prior year period, which represents a 19.7% increase. Net income per diluted share for the quarter was $4.25 compared to $3.10 in the prior year period. Year to date, net income per diluted share was $8.53 compared to $6.79 in the comparable prior year period.
Net new business awards entering backlog in the second quarter increased 28.2% from the prior year to 795.7 million, resulting in a book-to-bill of 1.13. Ending backlog as of June 30, 2026 was approximately 3 billion, an increase of 4.9% from the prior year. We project that approximately 1.96 billion of backlog will convert to revenue in the next 12 months. Backlog conversi